Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

The SK Telecom, iA Financial, Foxconn and Fujifilm-backed X-ray technology developer priced the offering at the top of its range.

The protein degradation drug developer's valuation has rocketed following an offering that achieved exits for Vertex Pharmaceuticals, Pfizer, Sanofi, Amgen and Merck & Co.

GlaxoSmithKline’s Action Potential Venture Capital fund led a series B-plus round that included TDK Ventures, Intel Capital and Applied Ventures.

Boston Children’s Hospital, Blue Cross Blue Shield of Massachusetts and Blue Shield of California have all invested in the children's behavioural healthcare provider.

Scienion has agreed to a cash and share acquisition by Cellink two decades after emerging from Max Planck Institute for Molecular Genetics.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Returning investor PPD co-led a $40m round for the remote clinical trials service, while Novartis, Amgen, Sanofi and Alphabet also doubled down on their commitments.

The patient communication app developer took its total funding past the $30m mark with a round co-led by Google's Gradient Ventures fund.